"Unacceptable would be not up the standard of care anywhere in the world. So, either shortened courses of chemotherapy [or] chemotherapy that isn't proven, that kind of thing," said Dr. Marianne Taylor, who conducted the Cancer Agency’s review.

In eight cases, the agency found that Katakkar's decisions led to severe, preventable patient harm. In four cases, the review found the prescribed treatment may have contributed to the patients' premature death.